GLP-1 Medications and Cancer Risk: What the Research Is Showing

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Compounded medications have not been studied in the cancer-risk trials described below, and no cancer prevention claims are made for compounded GLP-1 products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

A question is appearing more often in conversations between patients and their providers: could GLP-1 medications do something about cancer risk?

It sounds like an ambitious question. But the science behind it is grounded in something well-established: obesity is one of the strongest modifiable risk factors for cancer. And GLP-1 receptor agonists, the drug class that includes FDA-approved branded medications like Ozempic, Wegovy, Mounjaro, and Zepbound, reduce body weight, chronic inflammation, and insulin resistance. Each of those factors plays a direct role in the biology of obesity-related cancer.

Researchers are now examining what happens to cancer incidence in large populations using these medications. The data is early, but it is generating serious scientific interest.

Here is an honest, evidence-based look at what researchers have found so far, what we still do not know, and why this topic matters for anyone managing obesity.

---

Why Obesity Increases Cancer Risk

Before looking at what GLP-1 medications might do, it helps to understand what obesity does to the biology that governs cancer risk.

Obesity is not simply excess weight. It is a metabolic state characterized by persistent changes in how the body manages energy, hormones, and inflammation. These changes create conditions that favor cancer development in at least 13 recognized cancer types, including colorectal, endometrial, breast (postmenopausal), kidney, liver, and pancreatic cancer.

A 2019 review in *Metabolism: Clinical and Experimental* identified three interconnected mechanisms through which obesity promotes cancer (PMID 30445141, Avgerinos et al.):

Chronic low-grade inflammation. Adipose tissue in people with obesity releases pro-inflammatory cytokines including TNF-alpha, interleukin-6, and C-reactive protein at elevated levels. This systemic inflammation creates an environment where cellular mutations are more likely to evade immune surveillance and proliferate.

Insulin and IGF-1 signaling dysregulation. Obesity promotes insulin resistance, which drives compensatory hyperinsulinemia. Elevated insulin and insulin-like growth factor 1 (IGF-1) act on tumor cells as growth signals. Cancer cells that express insulin receptors respond to this environment by proliferating more aggressively.

Adipokine dysregulation. Adipose tissue secretes hormones called adipokines. In people with obesity, levels of leptin (pro-proliferative) rise while adiponectin (anti-proliferative) levels fall. This shift in the balance between these two adipokines creates a hormonal environment that supports cancer cell growth.

These are not theoretical concerns. They are measurable changes that occur in most people with obesity and that correspond to elevated cancer incidence in population-level data.

---

What GLP-1 Medications Do to These Risk Drivers

GLP-1 receptor agonists do not target cancer. They target the metabolic and inflammatory drivers that link obesity to cancer risk.

Weight loss itself reduces circulating leptin, improves adiponectin levels, reduces systemic inflammation, and improves insulin sensitivity. These downstream effects of weight reduction are exactly what researchers expected to see correlated with reduced cancer risk in long-term follow-up of GLP-1 users.

There is also emerging evidence that GLP-1 receptors are expressed in tissue beyond the gut, pancreas, and brain, including in certain immune cells, raising the possibility that GLP-1 receptor agonism has direct anti-inflammatory effects that are partially independent of weight loss. This is an active area of research and no clinical conclusions have been established from it.

What researchers have studied directly is cancer incidence in real-world populations taking GLP-1 medications.

---

Colorectal Cancer: The Strongest Signal So Far

The clearest data on GLP-1 medications and cancer comes from colorectal cancer research.

A 2026 systematic review and network meta-analysis published in *Diabetes/Metabolism Research and Reviews* examined the association between GLP-1 receptor agonists and the risk of colon cancer in adults with type 2 diabetes or obesity (PMID 41668634, Guo et al.). Across the included studies, GLP-1 receptor agonist use was associated with a reduced risk of colon cancer compared to other glucose-lowering medications and placebo. The authors noted that the biological plausibility of this association is supported by the reduction of obesity-related inflammation and improved metabolic control associated with GLP-1 receptor agonist therapy.

A 2026 comprehensive meta-analysis published in *Frontiers in Pharmacology* extended this analysis to the broader category of gastrointestinal malignancies (PMID 41743116, Wali et al.). The review found that GLP-1 receptor agonist use was associated with reduced risk of gastrointestinal cancers in populations with obesity and type 2 diabetes. The authors described the evidence as "reassessing" the cancer risk profile of this drug class, meaning GLP-1 medications appear to carry a more favorable cancer risk profile than previously appreciated.

These are observational findings from populations using FDA-approved branded GLP-1 medications, not compounded semaglutide or tirzepatide. They cannot be used to draw conclusions about compounded products.

<img src="/images/articles/glp1-medications-inflammation-crp-research-hero.jpg" alt="Scientific visualization of inflammation markers, warm amber tones, Prescriva health education visual style" />

---

Hematologic Cancers: Early Signals with Important Caveats

A January 2026 retrospective cohort study published in *EClinicalMedicine* examined the incidence of hematologic malignancies, including leukemia, lymphoma, and myeloma, in people with type 2 diabetes using GLP-1 receptor agonists versus SGLT2 inhibitors (PMID 41583363, Irons et al.). The study used electronic health records from a large real-world database.

The researchers found lower incidence of hematologic malignancies in the GLP-1 receptor agonist group compared to the SGLT2 inhibitor group. They were careful to note that this is observational data with important confounders: people prescribed GLP-1 medications may differ systematically from those prescribed SGLT2 inhibitors in ways that affect cancer risk, including baseline weight, comorbidities, and other medication use.

This study is hypothesis-generating, not confirmatory. It does suggest that the potential cancer risk-modifying effects of GLP-1 medications may extend beyond gastrointestinal cancers, but rigorous prospective trials would be needed to establish causality.

---

GLP-1 Medications in Cancer Survivorship

A different angle on this question involves people who already have a cancer diagnosis. A 2026 narrative review published in *Postgraduate Medical Journal* examined the potential role of GLP-1 receptor agonists in cancer survivorship (PMID 42059880, Hatzis et al.).

The review identified several areas where GLP-1 medications may be relevant for cancer survivors: managing the metabolic consequences of cancer treatment (including weight gain from chemotherapy or hormone therapy), improving insulin resistance associated with certain cancer treatments, and reducing the cardiovascular risk that is elevated in many long-term cancer survivors.

The authors did not claim that GLP-1 medications treat cancer or prevent recurrence. They identified obesity management and metabolic optimization in survivors as an area where GLP-1 medications may have a clinical role, with appropriate medical supervision.

---

What This Means for Patients: An Honest Assessment

The data reviewed here represents a genuine and growing body of evidence suggesting that GLP-1 receptor agonists may reduce the risk of certain obesity-related cancers. The mechanistic rationale is sound. The early epidemiological signals are consistent.

Several important limitations must be acknowledged:

The studies examine FDA-approved branded GLP-1 medications (semaglutide as Ozempic and Wegovy; tirzepatide as Mounjaro and Zepbound) in populations with type 2 diabetes or obesity. No data specifically addresses compounded semaglutide or tirzepatide, and no cancer prevention claim is made or implied for compounded versions of these medications.

The populations studied have type 2 diabetes or obesity, which carry independent cancer risk elevation. The reduction in cancer risk observed in GLP-1 users may reflect the effects of weight loss and metabolic improvement rather than direct drug actions, or a combination of both.

None of these studies were designed or powered as cancer prevention trials. They are largely observational analyses and retrospective cohort studies. Randomized controlled trials with cancer incidence as a primary endpoint do not yet exist for GLP-1 medications.

GLP-1 medications, including compounded versions, are not FDA-approved for cancer risk reduction and should not be considered for that purpose.

What these findings do suggest is that the benefits of GLP-1-mediated weight loss and metabolic improvement extend beyond what is visible on a scale. Managing obesity is not only a weight management intervention; it is a metabolic intervention with systemic implications. The cancer risk research adds to an accumulating picture of what comprehensive obesity treatment may do for long-term health.

---

The Takeaway

Obesity is linked to at least 13 cancer types through mechanisms involving chronic inflammation, insulin dysregulation, and adipokine imbalance. GLP-1 receptor agonists act on all three of these pathways.

Emerging research, including a 2026 systematic review and network meta-analysis (PMID 41668634), a 2026 meta-analysis of gastrointestinal malignancies (PMID 41743116), and a 2026 retrospective cohort study on hematologic malignancies (PMID 41583363), consistently shows an association between GLP-1 receptor agonist use and reduced incidence of certain obesity-related cancers.

This evidence is encouraging, but not conclusive, and it applies to FDA-approved branded medications in studied populations. These findings should inform conversations with your healthcare provider about the broad benefits of addressing obesity, not decisions about using medications for cancer prevention.

If you have questions about whether a medically supervised weight management program is right for your health situation, a licensed provider at Prescriva can evaluate your individual circumstances.

*This article is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making any treatment decisions.*

---

Explore related articles:

• [GLP-1 Medications and Inflammation Research](/resources/glp1-medications-inflammation-research)
• [GLP-1 Medications and Cardiovascular Health](/resources/glp1-medications-cardiovascular-health)
• [GLP-1 Medications and Insulin Resistance](/resources/glp1-medications-insulin-resistance)
• [Semaglutide Long-Term Effects](/resources/semaglutide-long-term-effects)

References:

1. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. *Metabolism.* 2019;93:121-135. PMID: 30445141

1. Guo M, et al. Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis. *Diabetes/Metabolism Research and Reviews.* 2026 Feb. PMID: 41668634

1. Wali AF, et al. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies. *Frontiers in Pharmacology.* 2026. PMID: 41743116

1. Irons EE, et al. Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records. *EClinicalMedicine.* 2026 Jan. PMID: 41583363

1. Hatzis G, et al. The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review. *Postgraduate Medical Journal.* 2026 Apr. PMID: 42059880